118 related articles for article (PubMed ID: 38477942)
1. HOXA1 silencing inhibits cisplatin resistance of oral squamous cell carcinoma cells via IκB/NF-κB signaling pathway.
Zhu R; Mao Y; Xu X; Li Y; Zheng J
Anticancer Drugs; 2024 Jul; 35(6):492-500. PubMed ID: 38477942
[TBL] [Abstract][Full Text] [Related]
2. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
3. Elevated microRNA-145 inhibits the development of oral squamous cell carcinoma through inactivating ERK/MAPK signaling pathway by down-regulating HOXA1.
Ding J; Sun D; Xie P
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31138758
[No Abstract] [Full Text] [Related]
4. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
[TBL] [Abstract][Full Text] [Related]
5. Long non‑coding RNA AFAP1‑AS1 facilitates the growth and invasiveness of oral squamous cell carcinoma by regulating the miR‑145/HOXA1 axis.
Li M; Yu D; Li Z; Zhao C; Su C; Ning J
Oncol Rep; 2021 Mar; 45(3):1094-1104. PubMed ID: 33650645
[TBL] [Abstract][Full Text] [Related]
6. Neuropilin-1 promotes epithelial-to-mesenchymal transition by stimulating nuclear factor-kappa B and is associated with poor prognosis in human oral squamous cell carcinoma.
Chu W; Song X; Yang X; Ma L; Zhu J; He M; Wang Z; Wu Y
PLoS One; 2014; 9(7):e101931. PubMed ID: 24999732
[TBL] [Abstract][Full Text] [Related]
7. HOXA1 is overexpressed in oral squamous cell carcinomas and its expression is correlated with poor prognosis.
Bitu CC; Destro MF; Carrera M; da Silva SD; Graner E; Kowalski LP; Soares FA; Coletta RD
BMC Cancer; 2012 Apr; 12():146. PubMed ID: 22498108
[TBL] [Abstract][Full Text] [Related]
8. Supramolecular nanodrug targeting CDK4/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma.
Zhao B; Qin X; Fu R; Yang M; Hu X; Zhao S; Cui Y; Guo Q; Zhou W
J Control Release; 2024 Apr; 368():623-636. PubMed ID: 38479445
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor of Growth 4 (ING4) Plays a Tumor-repressing Role in Oral Squamous Cell Carcinoma via Nuclear Factor Kappa-B (NF-kB)/DNA Methyltransferase 1 (DNMT1) Axis-mediated Regulation of Aldehyde Dehydrogenase 1A2 (ALDH1A2).
Cui Z; Sun S; Li J; Li J; Sha T; He J; Zuo L
Curr Cancer Drug Targets; 2022; 22(9):771-783. PubMed ID: 35388759
[TBL] [Abstract][Full Text] [Related]
10. miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling.
Lu M; Wang C; Chen W; Mao C; Wang J
DNA Cell Biol; 2018 Apr; 37(4):381-388. PubMed ID: 29364705
[TBL] [Abstract][Full Text] [Related]
11. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
12. WNT3 promotes chemoresistance to 5-Fluorouracil in oral squamous cell carcinoma via activating the canonical β-catenin pathway.
Zhang X; Sun K; Gan R; Yan Y; Zhang C; Zheng D; Lu Y
BMC Cancer; 2024 May; 24(1):564. PubMed ID: 38711026
[TBL] [Abstract][Full Text] [Related]
13. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
[TBL] [Abstract][Full Text] [Related]
14. UBE2L3 promotes squamous cell carcinoma progression in the oral cavity and hypopharynx via activating the NF-κB signaling by increasing IκBα degradation.
Cui Z; Sun S; Li J; Li J; Sha T; He J; Zuo L
Cell Biol Int; 2022 May; 46(5):806-818. PubMed ID: 35128752
[TBL] [Abstract][Full Text] [Related]
15. Long Non-Coding RNA NKILA Reduces Oral Squamous Cell Carcinoma Development Through the NF-KappaB Signaling Pathway.
Hu D; Zhong T; Dai Q
Technol Cancer Res Treat; 2020; 19():1533033820960747. PubMed ID: 33143574
[TBL] [Abstract][Full Text] [Related]
16. Circ_0109291 Promotes Cisplatin Resistance of Oral Squamous Cell Carcinoma by Sponging miR-188-3p to Increase
Gao F; Han J; Wang Y; Jia L; Luo W; Zeng Y
Cancer Biother Radiopharm; 2022 May; 37(4):233-245. PubMed ID: 32758011
[No Abstract] [Full Text] [Related]
17. Vitamin D promotes the cisplatin sensitivity of oral squamous cell carcinoma by inhibiting LCN2-modulated NF-κB pathway activation through RPS3.
Huang Z; Zhang Y; Li H; Zhou Y; Zhang Q; Chen R; Jin T; Hu K; Li S; Wang Y; Chen W; Huang Z
Cell Death Dis; 2019 Dec; 10(12):936. PubMed ID: 31819048
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.
Sudo S; Kajiya H; Okano S; Sasaki M; Katsumata Y; Ohno J; Ikebe T; Hiraki A; Okabe K
Cancer Sci; 2020 Apr; 111(4):1113-1123. PubMed ID: 32012401
[TBL] [Abstract][Full Text] [Related]
19. Anticancer Efficacy and Mechanism of Amentoflavone for Sensitizing Oral Squamous Cell Carcinoma to Cisplatin.
Chen CH; Huang YC; Lee YH; Tan ZL; Tsai CJ; Chuang YC; Tu HF; Liu TC; Hsu FT
Anticancer Res; 2020 Dec; 40(12):6723-6732. PubMed ID: 33288565
[TBL] [Abstract][Full Text] [Related]
20. Propranolol inhibits cell viability and expression of the pro-tumorigenic proteins Akt, NF-ĸB, and VEGF in oral squamous cell carcinoma.
Shibuya CM; Tjioe KC; Oliveira SHP; Bernabé DG
Arch Oral Biol; 2022 Apr; 136():105383. PubMed ID: 35240444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
